Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
Authors
Keywords
-
Journal
Lancet Haematology
Volume 9, Issue 3, Pages e190-e199
Publisher
Elsevier BV
Online
2022-03-01
DOI
10.1016/s2352-3026(22)00034-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
- (2021) Othman Al-Sawaf et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
- (2020) Othman Al-Sawaf et al. BLOOD
- Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial
- (2020) Kirsten Fischer et al. BLOOD
- Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
- (2020) Annika Scheffold et al. Current Oncology Reports
- Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
- (2020) Eugen Tausch et al. BLOOD
- Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm
- (2020) Manju Sengar et al. Current Hematologic Malignancy Reports
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
- (2020) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The evolving treatment landscape of chronic lymphocytic leukemia
- (2019) Luana Schiattone et al. CURRENT OPINION IN ONCOLOGY
- Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
- (2019) John G. Gribben BRITISH JOURNAL OF HAEMATOLOGY
- Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
- (2018) Sabina Kersting et al. Clinical Lymphoma Myeloma & Leukemia
- Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
- (2018) Jan A. Burger et al. Nature Reviews Clinical Oncology
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
- (2016) Gabor Kovacs et al. JOURNAL OF CLINICAL ONCOLOGY
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
- (2015) A C Rawstron et al. LEUKEMIA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started